---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-108333"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:48:33.888073+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics completes $600M convertible note offering due 2031

## Summary
- Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.
- Effective coupon 1.125%; increased to 1.7308% due to anticipated Swiss withholding tax.
- Initial conversion price ~$76.56 per share, a 45% premium to the $52.80 closing price on March 10, 2026.
- Notes mature March 1, 2031; unregistered, sold to QIBs under Rule 144A; proceeds for general corporate purposes.
- Holders may convert at any time before maturity; company may redeem after March 6, 2029 if stock price condition met.

## SEC filing metadata
- accession: 0001193125-26-108333
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/crsp-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-108333
- JSON: https://secwatch.observer/filing/0001193125-26-108333.json
- Plain text: https://secwatch.observer/filing/0001193125-26-108333.txt

## Source-grounded claims
- claim_id: 446d0629ab6639aa5efc249a5ae582213f76a1ff
  claim: CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.
  evidence_excerpt: On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm
- claim_id: fbb4a778578d8899f2feae408f3919c0743e8928
  claim: CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).
  evidence_excerpt: On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312526108333/0001193125-26-108333-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.